Evidence map›Paper›PMID 42049753›Full record

ArticleNature communications2026

Generation of mixed-valency, modular multispecific antibodies using disulfide-linked Fc-FcγR complexes.

Miso Park, Kevin Ly, Bea Parcutela, Hyeran Choi, Carmina Ladra, Asaul Gonzalez, Yead Jewel, Hyunjun Kang, Melissa Valerio, Aparna Krishnan and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Miso ParkDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-9914-4351
Kevin LyDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Bea ParcutelaDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-5912-8071
Hyeran ChoiDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Carmina LadraDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Asaul GonzalezDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Yead JewelDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Hyunjun KangDepartment of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Melissa ValerioDepartment of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Aparna KrishnanDepartment of Medical Oncology and Therapeutics Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Timothy W SynoldDepartment of Medical Oncology and Therapeutics Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-4075-2544
Le Xuan Truong NguyenDepartment of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-5464-0861
Guido MarcucciDepartment of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-3983-5908
John C WilliamsDepartment of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. jcwilliams@coh.org.ORCID http://orcid.org/0000-0002-0522-384X

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA033572
6 · The paper itself

Abstract

There is a strong need for multispecific antibodies that possess favorable clinical properties and can be generated through a simple and efficient process. Here, we repurpose the native IgG Fc-FcγR interaction into a universal, covalent docking site using only a single engineered disulfide bond, providing a simple solution to bypass the complex, bespoke engineering typically required for multispecific antibody design. The resulting Fc-FcγR complex forms a homodimeric Fc with one ligand, with the FcγR offering both N- and C-termini for independent functionalization, enabling single- or dual-payload formats, including masked designs for conditional activation. Introducing the disulfide between Fc (A330C) and FcγRIIIa (I106C) yields stable, covalently linked complexes that do not require post-expression modification, are compatible with standard mammalian expression, and support payloads such as anti-CD3, anti-CD28, IL-2, and protease-activated IL-2. These compounds exhibit potent, antigen-selective cytotoxicity in vitro and in vivo, with tunable avidity and reduced off-target activity. This plug-and-play platform overcomes key developability bottlenecks and enables rapid, scalable creation of next-generation antibody therapeutics.

Indexed as

Antibodies, BispecificDisulfidesImmunoglobulin Fc FragmentsReceptors, IgGAnimalsHumansImmunoglobulin GMiceProtein EngineeringAntibodies, BispecificDisulfidesImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, IgG

Identifiers

PMID42049753
PMCPMC13328583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.